RSV is the most common cause of hospitalization in babies, but Sanofi is one of a few companies producing a shot that can ...

The FDA has expanded the approval of mResvia to include active immunization in high-risk individuals 18 through 59 years of age.

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five ...

A prominent paediatrician on Sunday urged people to take more precautions against a common virus known as RSV, saying cases ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

The FDA has approved clesrovimab, marketed as Enflonsia, for the prevention of RSV lower respiratory tract disease in ...

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...